{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:23:56Z","timestamp":1774463036611,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[1999,1]]},"DOI":"10.1016\/s0028-3908(98)00165-8","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T22:55:58Z","timestamp":1027637758000},"page":"109-119","source":"Crossref","is-referenced-by-count":25,"title":["GlycineB antagonists and partial agonists in rodent models of Parkinson\u2019s disease\u2014comparison with uncompetitive N-methyl-d-aspartate receptor antagonist"],"prefix":"10.1016","volume":"38","author":[{"given":"M.","family":"Karcz-Kubicha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Danysz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0028-3908(98)00165-8_BIB1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90437-5","article-title":"Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex","volume":"168","author":"Berger","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB2","first-page":"578","article-title":"The atypical neuroleptic profile of the glycine\/N-methyl-D-aspartate receptor antagonist, l-701,324, in rodents","volume":"277","author":"Bristow","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01258633","article-title":"The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice","volume":"75","author":"Carlsson","year":"1989","journal-title":"J. Neural Transm."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Interaction between glutamatergic and monoaminergic systems within the basal ganglia\u2014implications for schizophrenia and Parkinson\u2019s disease","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02246054","article-title":"Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms","volume":"119","author":"Carroll","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF02247140","article-title":"Effect of NMDA-insensitive and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning","volume":"102","author":"Chiamulera","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2165\/00002512-199202020-00005","article-title":"Current drug therapy for Parkinson\u2019s disease. A review","volume":"2","author":"Coleman","year":"1992","journal-title":"Drug Aging"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0091-3057(94)90506-1","article-title":"Glutamate antagonists have different effects on spontaneous locomotor activity in rats","volume":"48","author":"Danysz","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02253435","article-title":"Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine","volume":"7","author":"Danysz","year":"1994","journal-title":"J. Neural Transm.-Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB10","first-page":"261","article-title":"Glutamate in CNS disorders\u2014a revived target for drug development","volume":"8","author":"Danysz","year":"1995","journal-title":"Drug News Perspect."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2014Preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02260897","article-title":"Neuroleptic induced catalepsy as a model of Parkinson\u2019s disease. II. Effect of glutamate antagonists","volume":"2","author":"Elliott","year":"1990","journal-title":"J. Neural Transm. Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0404.1973.tb01296.x","article-title":"The effect of adding amantadine to optimum L-DOPA dosage in Parkinson\u2019s syndrome","volume":"49","author":"Feiling","year":"1973","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB14","first-page":"12","article-title":"Role of catechol autoxidation in the degeneration of dopamine neurons","volume":"129","author":"Fornstedt","year":"1990","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02256627","article-title":"Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats","volume":"10","author":"Gossel","year":"1995","journal-title":"J. Neural Transm. Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"N-methyl-D-aspartate antagonists in the treatment of Parkinson\u2019s disease","volume":"48","author":"Greennamyre","year":"1991","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1476-5381.1993.tb13768.x","article-title":"Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology","volume":"110","author":"Hargreaves","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4522(96)00036-X","article-title":"Impairments of movement initiation and execution induced by a blockade of dopamine D-1 or D-2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors","volume":"73","author":"Hauber","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0028-3908(97)00130-5","article-title":"Anxiolytic activity of glycine-B antagonists and partial agonists\u2014no relation to intrinsic activity in the patch clamp","volume":"36","author":"Karcz-Kubicha","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(95)00200-5","article-title":"Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse","volume":"280","author":"Kaur","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-2236(89)90007-6","article-title":"Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson\u2019s disease","volume":"12","author":"Klockgether","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.410280411","article-title":"NMDA antagonists potentiate antiparkinsonian action of L-DOPA in monoamine-depleted rats","volume":"28","author":"Klockgether","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB23","first-page":"349","article-title":"Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists-relationship with phencyclidine-like behavioral effects","volume":"252","author":"Koek","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB24","first-page":"91","article-title":"Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties","volume":"43","author":"Kornhuber","year":"1994","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01253108","article-title":"The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior","volume":"87","author":"Kretschmer","year":"1992","journal-title":"J. Neural Transm."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01276431","article-title":"Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats","volume":"95","author":"Kretschmer","year":"1994","journal-title":"J. Neural Transm."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-2999(97)01047-9","article-title":"ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats","volume":"331","author":"Kretschmer","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB28","first-page":"945","article-title":"Glycine site agonists exhibit subunit specific effects on NMDA receptors expressed in Xenopus oocytes","volume":"23","author":"Krueger","year":"1997","journal-title":"Soc. Neurosci. Abst."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB29","first-page":"147","article-title":"The neurotoxicity of MPTP and its relationship to parkinsonism","volume":"1","author":"Langston","year":"1987","journal-title":"ISI Atlas Sci. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00813745","article-title":"D-cycloserine: agonist turned antagonist","volume":"6","author":"Lanthorn","year":"1994","journal-title":"Amino Acids"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-8993(96)00693-2","article-title":"MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats","volume":"736","author":"Marin","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0014-2999(96)00576-6","article-title":"The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats","volume":"314","author":"McAllister","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0149-7634(96)00036-X","article-title":"Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action","volume":"21","author":"Mitchell","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00008877-199508000-00010","article-title":"Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset","volume":"6","author":"Mitchell","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jnnp.55.7.630-a","article-title":"A pilot study of N-Methyl-D-Aspartate (NMDA) antagonist in Parkinson\u2019s disease [6]","volume":"55","author":"Montastruc","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.870090226","article-title":"N-methyl-D-aspartate (NMDA) antagonist and Parkinsons disease\u2014a pilot study with dextromethorphan","volume":"9","author":"Montastruc","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(93)90085-V","article-title":"NMDA receptor antagonists inhibit catalepsy induced by either dopamine-D1 or dopamine-D2 receptor antagonists","volume":"237","author":"Moore","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0149-7634(96)00031-0","article-title":"Dopamine\/glutamate interaction as studied by combining turning behaviour and c-fos expression","volume":"21","author":"Morelli","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB39","doi-asserted-by":"crossref","first-page":"261S","DOI":"10.1016\/0197-0186(92)90249-Q","article-title":"Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors","volume":"20","author":"Morelli","year":"1992","journal-title":"Neurochem. Int."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(93)90969-O","article-title":"Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor\/channel complex","volume":"239","author":"Murata","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000119538","article-title":"Levodopa and dopamine agonists in the treatment of Parkinson\u2019s disease: advantages and disadvantages","volume":"34","author":"Ogawa","year":"1994","journal-title":"Eur. Neurol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02250917","article-title":"The role of excitatory amino acids in experimental models of Parkinson\u2019s disease","volume":"8","author":"Ossowska","year":"1994","journal-title":"J. Neural Transm.-Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02260969","article-title":"Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis","volume":"7","author":"Ossowska","year":"1994","journal-title":"J. Neural Transm.-Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-reduced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB45","first-page":"1264","article-title":"Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological biochemical and behavioral characterization","volume":"283","author":"Parsons","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB46","unstructured":"Paxinos, G., Watson, C., 1986. The rat brain in stereotaxic coordinates. Academic Press, Sydney."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB47","first-page":"841","article-title":"Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a\/NR2a and NR1a\/NR2b subunit assemblies expressed in permanently transfected mouse fibroblast cells","volume":"48","author":"Priestley","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02260076","article-title":"Efficacy of memantine and NMDA receptor antagonist, in the treatment of Parkinson\u2019s disease","volume":"4","author":"Rabey","year":"1992","journal-title":"J. Neural Transm.-Parkinsons"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0149-7634(96)00044-9","article-title":"Behavioural pharmacology of glutamate receptors in the basal ganglia","volume":"21","author":"Schmidt","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00806920","article-title":"Anticataleptic potencies of glutamate-antagonists","volume":"1","author":"Schmidt","year":"1991","journal-title":"Amino Acids"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB51","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.208.7.1168","article-title":"Amantadine in the treatment of Parkinson\u2019s disease","volume":"208","author":"Schwab","year":"1969","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01277594","article-title":"Memantine, amantadine, and l-deprenyl potentiate the action of l-DOPA in monoamine-depleted rats","volume":"98","author":"Skuza","year":"1994","journal-title":"J. Neural. Transm.-Gen. Sect."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02336139","article-title":"Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice","volume":"97","author":"Stauch Slusher","year":"1994","journal-title":"J. Neural. Transm.-Gen. Sect."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0166-2236(90)90106-K","article-title":"The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones","volume":"13","author":"Smith","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB55","first-page":"50","article-title":"Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior","volume":"235","author":"Snell","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(93)90387-W","article-title":"Facilitation of dopamine-D1 receptor-dependent but not dopamine d(1)\/d(2) receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse","volume":"250","author":"Starr","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0149-7634(96)00039-5","article-title":"Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson\u2019s disease","volume":"21","author":"Starr","year":"1997","journal-title":"Neurosici. Biobehav. Rev."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/syn.890070103","article-title":"Paradoxical anticonvulsant activity of the gamma-aminobutyrate antagonist bicuculline methiodide in the rats striatum","volume":"7","author":"Turski","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/S0028-3908(98)00165-8_BIB59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/S0028-3908(98)00165-8_BIB60","first-page":"105","article-title":"Neurochemical responses to 6-hydroxydopamine and L-DOPA therapy: implication for Parkinson\u2019s disease","volume":"32","author":"Zigmond","year":"1992","journal-title":"Ann. Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390898001658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390898001658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T17:22:24Z","timestamp":1555608144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390898001658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["S0028390898001658"],"URL":"https:\/\/doi.org\/10.1016\/s0028-3908(98)00165-8","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}